Neuromyelitis optica (NMO) and autoimmune thyroiditis

Sreenivasa Rao Sudulagunta¹,*, Mahesh Babu Sodalagunta², Hadi Khorram³, Mona Sepehrar⁴, Mohammed Aheta Sham⁵, Ranjitha Nidsale Sudarshan⁶, and Rekha Gangadharappa⁶

¹Columbia Asia Hospital, Bangalore, India, ²Department of General Medicine, K.S. Hegde Medical College, Mangalore, India, ³Department of Otolaryngology, Dr. B.R. Ambedkar Medical College, Bangalore, India, ⁴Department of Pharmacy, Baptist Hospital, Bangalore, India, ⁵Department of Radiology, Dr. B.R. Ambedkar Medical College, Bangalore, India, and ⁶Department of General Medicine, Dr. B.R. Ambedkar Medical College, Bangalore, India

*Correspondence address. Columbia Asia Hospital, Kirloskar Business Park, Hebbal, Bangalore 560024, India. Tel: +91-8147572745; Fax: +91 80 4179 1002; E-mail: dr.sreenivas@live.in

Abstract

Neuromyelitis optica (NMO or Devic’s syndrome) is a rare demyelinating disease of the CNS that predominantly affects the spinal cord and optic nerves and shares many clinical and radiological features with multiple sclerosis (MS). The association of NMO with autoimmune thyroiditis has been reported very rarely. Early differentiation between NMO and MS is very important because they have different natural courses and treatment regimens. We report a case regarding a 53-year-old woman who was admitted initially with hiccups and paraesthesias, but was not evaluated during first two episodes and presented with severe progression of NMO.

Patient was found to have autoimmune thyroiditis with lymphocytic infiltration of thyroid which progressed to hypothyroidism. NMO was diagnosed with seropositivity for NMO-IgG and longitudinally extensive spinal cord lesions (three or more spinal segments). Patient poorly responded to treatment due to the lack of early diagnosis and aggressive immunosuppressant therapy.

INTRODUCTION

Neuromyelitis optica (NMO; Devic’s syndrome) is a demyelinating disease of the CNS that predominantly affects the spinal cord and optic nerves and shares many clinical and radiological features with multiple sclerosis (MS) [1–3]. NMO is considered as a disease entity after the discovery of a novel, pathogenic auto-antibody (NMO-IgG or AQP4-Ab) in 2004 [4, 5].

NMO is a rare syndrome constituting <1% of demyelinating disease [6, 7]. Clinical, MRI and spinal fluid features from several case series are illustrated in Table 1 (http://www.medscape.com/viewarticle/446182_4). Prevalence estimates of prevalence of NMO in Japan is ~14 per 1 000 000 [8], and of northwest England is ~4 per 1 000 000 with a female-to-male ratio of 3 : 1. The Mayo Clinic proposed a revised set of criteria for diagnosis in 2006 (Table 2).

Hashimoto’s thyroiditis (chronic lymphocytic thyroiditis) is an autoimmune disease characterized by cell- and antibody-mediated immune processes against thyroid gland. Diagnosis requires observations of lymphocyte infiltration of thyroid and autoantibodies against thyroid peroxidase, thyroglobulin and thyroid hormone-stimulating receptor.
**Table 1: Clinical, MRI and spinal fluid features from several case series**

| Features                              | Number (proportion) |
|---------------------------------------|---------------------|
| Women/men                             | 87/36 (2.3 : 1)     |
| Average age at onset                  | 37                  |
| Monophasic/polyphasic                 | 72/40 (1.8 : 1)     |
| Optic neuritis presentation           | 50 (45%)            |
| Transverse myelitis presentation      | 43 (38%)            |
| Combined optic neuritis/transverse myelitis presentation | 19 (17%) |
| Autoimmune disease/antibodies         | 28/104 (27%)        |
| Antecedent infection                  | 22/91 (24%)         |
| Normal brain (MRI)                    | 48/63 (76%)         |
| Abnormal spinal cord (MRI)            | 55/58 (95%)         |
| Cerebrospinal fluid (CSF) pleocytosis | 63/85 (74%)         |
| >50 cells/mm³                         | 27/84 (32%)         |
| CSF polymorphonucleocytes             | 34/67 (51%)         |
| CSF oligoclonal bands                 | 23/77 (30%)         |

**Table 2: Mayo clinic criteria for NMO**

**Absolute criteria:**
1. Optic neuritis
2. Acute myelitis

**Supportive criteria:**
1. Brain MRI not meeting criteria for MS at disease onset
2. Spinal cord MRI with contiguous T2-weighted signal abnormality extending over three or more vertebral segments, indicating a relatively large lesion in the spinal cord
3. NMO-IgG-seropositive status (The NMO-IgG test checks the existence of antibodies against the aquaporin-4 antigen.)

**CASE REPORT**

A 53-year-old woman was admitted in a local hospital on November 2013 with complaints of hiccups, vomiting and paraesthesias of left upper and lower limb from 5 days. Patient completely recovered in a period of 30 days. Only thyroid profile was abnormal, which was suggestive of hyperthyroidism for which she took no medication (Table 3). In July 2014, patient was admitted with complaints of weakness of bilateral lower limbs and left upper limb along with band-like sensation around the chest at the T4 level. Patient also complained of difficulty in seeing distant objects in right eye. An MRI scan of brain and spine revealed lesion in the spinal cord at the levels of C2–C5, enhancing signal was seen at the levels of C3–C5.

Patient was given injection methylprednisolone 1 g intravenously for a period of 5 days and oral steroids for 4 weeks. However, the thyroid function tests were normal during that episode (Table 3). In February 2015, patient was admitted with fever, cough with expectoration, breathlessness, paraesthesias and diminished vision. She was diagnosed with left lower lobe pneumonia and treated. In March 2015, patient was brought to emergency room with complaints of bilateral lower limb weakness, bilateral upper limb weakness (distal > proximal) and band-like sensation over the chest and hiccups. Mini-Mental Status Examination (MMSE) was 28/30 (Table 4). Vision was diminished to counting fingers in right eye. Other cranial nerves were normal.

Hypertonia was noted in all limbs. Power was 3/5 bilaterally proximally and 2/5 distally in upper limbs. Lower limb power was 0/5 on admission but improved to 1/5 in 15 days. Upper limb reflexes were 2+ and knee and ankle reflexes were 3+. Babinski’s reflex was present bilaterally. Loss of joint position and vibration sense till bilateral anterior superior iliac spine was revealed. Abdominal reflex was absent.

Antibodies to HSV1, HSV2, CMV, EBV, HBV, VZV, HCV and HIV in serum and cerebrospinal fluid, as well as sarcoidosis and tumor markers in serum, revealed no abnormality. Polymerase chain reaction in CSF for HSV1 and HSV2 was negative. Cerebrospinal fluid analysis demonstrated no oligoclonal bands. Immunological tests for ANA titer were 1 : 320; tests for anti-extractable nuclear antigen, anti-dsDNA, anti-cardiolipin, anti-β2GPI, lupus cells and cryoglobulins were negative. A thyroid profile was suggestive of hypothyroidism (Table 3). Laboratory studies confirmed the presence of antithyroid antibodies (Table 5).

MRI brain and spine revealed (i) hyperintensity in the cervical cord at lower half of C6 and upper half of C7 vertebral body (Figs 1 and 2), (ii) hyperintensity in the thoracic cord at the level of T7, T8 and T9 (Figs 3 and 4) and (iii) hyperintensity in the right optic nerve head (Fig. 5). Fine needle aspiration of thyroid confirmed lymphocytic infiltration (Figs 6 and 7). Serology was positive for NMO-IgG. Patient was started on methylprednisolone 1 g/day for 5 days and azathioprine (2.5–3 mg/kg/day). Patient showed marginal improvement in motor symptoms. Patient was started on thyrroxine 25 µg and later increased to 75 µg.

**DISCUSSION**

Devic’s disease is a severe idiopathic immune-mediated inflammatory demyelinating disease that predominantly involves the spinal cord and optic nerves. The cardinal clinical features are longitudinally extensive transverse myelitis and optic neuritis.
Several differences exist in the characteristics and outcomes of patients with the monophasic and relapsing forms (Table 6).

The NMO-IgG autoantibody is highly specific (91%; 85–99%) and sensitive (73%; 58–76%), and has less common occurrence in MS. Its target antigen is AQP4, a richly distributed water-pump channel in the central spinal cord, hypothalamus, periventricular area and periaqueductal area. Spinal cord histopathology in NMO found loss of AQP4 in acute inflammatory lesions surrounding immunoglobulin and complement-deposited hyalinized small vessels.

Intravenous methylprednisolone 1 g daily for 5 days is the first-line therapy. Nakamura et al. [9] suggested a neuroprotective effect of high-dose steroids when given within first 2–3 days after...
onset of optic neuritis. Many severe NMO attacks respond inadequately to corticosteroid treatment. Plasma exchange and intravenous immunoglobulin were also tried for acute attacks.

Interferons and other MS therapies, such as natalizumab and fingolimod, may aggravate NMO as reported by some studies such as Min et al. [10] and Jacob et al. [11]. Current options are azathioprine, mycophenolate mofetil, rituximab, mitoxantrone, cyclophosphamide, methotrexate, intravenous immunoglobulin and prednisone. Rituximab (anti-CD20) has a rapid onset of action (full activity in 2 weeks) and less frequent dosing (two infusions every 6 months). In the absence of comparative controlled trials, no single drug is the best for every patient with NMO.

The association of NMO with autoimmune thyroiditis has been reported very rarely [12], even though autoimmune diseases occur frequently in patients with other autoimmune diseases. Steady progression of autoimmune thyroiditis from hyperthyroidism to hypothyroidism was noted over a period of 2 years. Early diagnosis and aggressive immunosuppressive treatment is of paramount importance in management of NMO. However, its role in autoimmune thyroiditis is not clearly known. IgG-NMO testing is very useful in diagnosis even if clinical and para-clinical autoimmune indices are available. Long-term immunosuppressive treatment is required to prevent relapses.

Guarantor: S. Sreenivasa Rao.

CONFLICT OF INTEREST STATEMENT
None declared.

REFERENCES
1. Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 2012;9:14.
2. Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 1999;53:1107–14.
3. Kitley J, Leite MI, Nakashima I, Waters P, McNeillis B, Brown R, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 2012;135:1834–49.
4. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202:473–7.
5. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittoc S J, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106–12.

6. Shibasaki H, McDonald WI, Kuroiwa Y. Racial modification of clinical picture of multiple sclerosis: comparison between British and Japanese patients. J Neurol Sci 1981;49:253–71.

7. Pálffy G. Multiple sclerosis in Hungary, including the Gypsy. In: Kuroiwa Y, Kurland LT (eds). Multiple Sclerosis, East and West. Fukuoka: Kyushu University Press, 1982, 149–58.

8. Kira JI. Multiple sclerosis in the Japanese population. Lancet Neurol 2003;2:117–27.

9. Nakamura M, Nakazawa T, Doi H, Hariya T, Omodaka K, Misu T, et al. Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica. Graefes Arch Clin Exp Ophthalmol 2010;248:1777–85.

10. Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler 2012;18:113–5.

11. Jacob A, Hutchinson M, Elsone I, Kelly S, Ali R, Saukans I, et al. Does natalizumab therapy worsen neuromyelitis optica? Neurology 2012;79:1065–6.

12. Sergio P, Mariana B, Alberto O, Claudia U, Oscar R, Pablo M, et al. Association of neuromyelitis optic (NMO) with autoimmune disorders: report of two cases and review of the literature. Clin Rheumatol 2010;29:1335–8.